The Role of Clinical Trials in Preclinical Alzheimer’s Disease Drug Development Programs
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2426-0266
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
The Role of Clinical Trials in Preclinical Alzheimer’s Disease Drug Development Programs ; day:6 ; month:5 ; year:2020 ; pages:1-3
The journal of prevention of Alzheimer's disease ; (6.5.2020), 1-3
- Classification
-
Medizin, Gesundheit
- Creator
-
Cummings, Jeffrey
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.14283/jpad.2020.28
- URN
-
urn:nbn:de:101:1-2020071122254931690774
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:49 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Cummings, Jeffrey
- SpringerLink (Online service)
Other Objects (12)
Drug candidates in clinical trials for Alzheimer’s disease
Heterogeneity of Alzheimer’s disease: consequence for drug trials?
BACE1 inhibitor drugs in clinical trials for Alzheimer’s disease
Study partner types and prediction of cognitive performance: implications to preclinical Alzheimer’s trials
Clinical trials of new drugs for Alzheimer disease
Recruitment into the Alzheimer Prevention Trials (APT) Webstudy for a Trial-Ready Cohort for Preclinical and Prodromal Alzheimer’s Disease (TRC-PAD)
Recent advances in Alzheimer’s disease: mechanisms, clinical trials and new drug development strategies
APOE effects on regional tau in preclinical Alzheimer’s disease
An olfactory ‘stress test’ may detect preclinical Alzheimer’s disease
Inflammatory plasma biomarkers in subjects with preclinical Alzheimer’s disease
Alzheimer’s Disease Drug Development Pipeline 2020
Advances in Alzheimer’s Disease Drug Development
Drug candidates in clinical trials for Alzheimer’s disease
Heterogeneity of Alzheimer’s disease: consequence for drug trials?
BACE1 inhibitor drugs in clinical trials for Alzheimer’s disease
Study partner types and prediction of cognitive performance: implications to preclinical Alzheimer’s trials
Clinical trials of new drugs for Alzheimer disease
Recruitment into the Alzheimer Prevention Trials (APT) Webstudy for a Trial-Ready Cohort for Preclinical and Prodromal Alzheimer’s Disease (TRC-PAD)
Recent advances in Alzheimer’s disease: mechanisms, clinical trials and new drug development strategies
APOE effects on regional tau in preclinical Alzheimer’s disease
An olfactory ‘stress test’ may detect preclinical Alzheimer’s disease
Inflammatory plasma biomarkers in subjects with preclinical Alzheimer’s disease
Alzheimer’s Disease Drug Development Pipeline 2020
Advances in Alzheimer’s Disease Drug Development
Drug candidates in clinical trials for Alzheimer’s disease
Heterogeneity of Alzheimer’s disease: consequence for drug trials?
BACE1 inhibitor drugs in clinical trials for Alzheimer’s disease
Study partner types and prediction of cognitive performance: implications to preclinical Alzheimer’s trials
Clinical trials of new drugs for Alzheimer disease
Recruitment into the Alzheimer Prevention Trials (APT) Webstudy for a Trial-Ready Cohort for Preclinical and Prodromal Alzheimer’s Disease (TRC-PAD)
Recent advances in Alzheimer’s disease: mechanisms, clinical trials and new drug development strategies
APOE effects on regional tau in preclinical Alzheimer’s disease
An olfactory ‘stress test’ may detect preclinical Alzheimer’s disease
Inflammatory plasma biomarkers in subjects with preclinical Alzheimer’s disease
Alzheimer’s Disease Drug Development Pipeline 2020